Flow Cytometry‐Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non‐Intensive Chemotherapy

Documenti analoghi

• Prognostic value of measurable residual disease in high‐risk MDS after intensive chemotherapy in HOVON‐SAKK studies
  di: Coen R. Veenstra, et al.
  Pubblicazione: (2026)
• The role of the primitive marker CD133 in CD34‐negative acute myeloid leukemia for the detection of leukemia stem cells
  di: Tom Reuvekamp, et al.
  Pubblicazione: (2024)
• Statistical inference using machine learning and classical techniques based on accumulated local effects (ALE)
  di: Okoli, Chitu
  Pubblicazione: (2023)
• D-branes
  di: Bachas, Constantin
  Pubblicazione: (2023)
• The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument
  di: Lidwine B. Mokkink
  Pubblicazione: (2016)